Mather Group’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Mather Group’s Portfolio XPH Stock Details XPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-294,318	Closed	-$13.8M	–	36
2015 Q3	$13.8M	Buy	294,318 +28,908	+11%	+$1.74M	3.64%	12
2015 Q2	$16.4M	Hold	265,410	–	–	4.32%	7
2015 Q1	$16.4M	Buy	265,410 +11,288	+4%	+$669K	4.32%	7
2014 Q4	$13.7M	Buy	254,122 +3,782	+2%	+$207K	3.95%	13
2014 Q3	$13.3M	Buy	250,340 +11,804	+5%	+$600K	4.08%	9
2014 Q2	$12.4M	Buy	238,536 +23,234	+11%	+$1.12M	4.02%	9
2014 Q1	$10.1M	Sell	215,302 -19,322	-8%	-$913K	3.7%	11
2013 Q4	$10.3M	Buy	234,624 +4,436	+2%	+$185K	3.93%	10
2013 Q3	$8.86M	Buy	230,188 +2,102	+0.9%	+$79.5K	3.68%	11
2013 Q2	$8.04M	Buy	+228,086	New	+$7.7M	3.47%	13

Other funds holding XPH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

PVH

Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Baird Financial Group Milwaukee, Wisconsin $64B AUM 22.64% 1-Year Est. Return

KHLMVGHM

Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet Tel Aviv, Israel $1.53B AUM 20.88% 1-Year Est. Return

Mather Group's XPH Position: Q4 2015 in Review

Mather Group sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q4 2015, closing a stake of 294,318 shares — an estimated $13.8M sold.

Mather Group first reported a position in XPH in Q2 2013 and held it in 10 quarters. The position peaked at $16.4M in Q2 2015. 76 funds tracked by Wall St. Rank hold XPH as of Q4 2015.

Mather Group reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q4 2015 after selling out during the quarter.
Mather Group sold 294,318 State Street SPDR S&P Pharmaceuticals ETF shares in Q4 2015, an estimated $13.8M.
Mather Group first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q2 2013 and held it in 10 quarters.
Mather Group's State Street SPDR S&P Pharmaceuticals ETF position peaked at $16.4M in Q2 2015.
76 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q4 2015.

Based on Mather Group's 13F filing for Q4 2015, filed 2 Feb 2016.